Showing results (1451-1460 of 1,518) with videos related to

Sort By:
Pageof 152
ESMO Open|October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateM Reck, T-E Ciuleanu, M Cobo, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Cancer Immunology, Immunotherapy : CII|February 17, 2019
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancerMartin Sebastian, Andreas Schröder, Birgit Scheel, et al.
The Lancet. Oncology|February 22, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 studyLuis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
The EMBO Journal|October 31, 2025
Auto-inhibition of PRC2 by the broadly expressed long isoform of AEBP2Marlena Mucha, Zhihao Lai, Nicholas J McKenzie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 22, 2025
Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLCTetsuya Mitsudomi, John V Heymach, Martin Reck, et al.
The New England Journal of Medicine|October 23, 2023
Perioperative Durvalumab for Resectable Non-Small-Cell Lung CancerJohn V Heymach, David Harpole, Tetsuya Mitsudomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 19, 2023
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 TrialByoung Chul Cho, Jong Seok Lee, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Pageof 152